Heterogeneity affecting outcome from acute stroke therapy making reperfusion worse

Stroke

Volumn 32, Issue 10, 2001, Pages 2318-2327

  Kent, Thomas A ^a,b   Soukup, Vicki M ^a   Fabian, Roderic H ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cytokines; Hyperglycemia; Reperfusion injury; Stroke; Tissue plasminogen activator

Indexed keywords

CYTOKINE; REACTIVE OXYGEN METABOLITE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; RISK ASSESSMENT; STROKE;

EID: 0034793545     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/hs1001.096588     Document Type: Article

References (169)

1. Tissue plasminogen activator for acute ischemic stroke
2. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. Stroke Treatment with Ancrod Trial
3. Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience
4. Ancrod in the treatment of acute ischemic stroke: A review of clinical data
5. Acute cerebellar edema following intra-arterial tissue plasminogen activator thrombolysis for basilar artery occlusion: Case report
6. Infusion of recombinant tissue plasminogen activator for treatment of basilar artery occlusion
7. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
8. Earlier treatment associated with better outcome in the NINDS tPA Stroke Study
9. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
10. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke
11. The evolution of acute stroke recorded by multimodal magnetic resonance imaging
12. Evaluation of early reperfusion and i.v. tPA therapy using diffusion- and perfusion-weighted MRI
13. Intra-arterial rtPA treatment of stroke assessed by diffusion- and perfusion-weighted MRI
14. Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat
15. Diffusion-weighted imaging: To treat or not to treat? That is the question
16. Diffusion-weighted MRI for diagnosis and treatment of ischemic stroke
17. Yield of diffusion-weighted MRI for detection of potentially relevant findings in stroke patients
18. Weighing the evidence on DWI: Caveat emptor
19. Diffusion-weighted MRI as an evolving standard of care in acute stroke
20. Temporal evolution of ischemic injury evaluated with diffusion-, perfusion-, and T2-weighted MRI
21. Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging
22. Brain tissue sodium is a ticking clock telling time after arterial occlusion in rat focal cerebral ischemia
23. Relation between cerebral blood flow and neurologic deficit resolution in acute ischemic stroke
24. Relationship between cerebral blood flow and the development of swelling and life-threatening herniation in acute ischemic stroke
25. 2O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy
26. Reperfusion injury: Demonstration of brain damage produced by reperfusion after transient focal ischemia in rats
27. Capillary perfusion in the occluded-reperfused canine myocardium: Evidence for slowed reflow
28. Acute blood glucose level and outcome from ischemic stroke: Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators
29. Ischemic brain edema and the osmotic gradient between blood and brain
30. Blood-brain barrier permeability and brain concentration of sodium, potassium, and chloride during focal ischemia
31. Role of blood-brain barrier permeability in focal ischemic brain edema
32. Brain edema and cerebrovascular permeability during cerebral ischemia in rats
33. Blood-brain barrier disruption and exacerbation of ischemic brain edema after restoration of blood flow in experimental focal cerebral ischemia
34. Ischemic cerebral edema: A review
35. Brain edema during ischemia and after restoration of blood flow. Measurement of water, sodium, potassium content and plasma protein permeability
36. Reperfusion increases neutrophils and leukotriene B4 receptor binding in rat focal ischemia
37. Advances in the vascular pathophysiology of ischemic stroke
38. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons
39. E-selectin in focal cerebral ischemia and reperfusion in the rat
40. P-selectin, and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion
41. Brain endothelium lack one of two pathways of P-selectin-mediated neutrophil adhesion
42. The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat
43. Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia
44. The mechanism of free radical generation in brain capillary endothelial cells after anoxia and reoxygenation
45. New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats
46. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat: Effects of neutrophil depletion
47. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat
48. Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia
49. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model
50. Postischemic treatment (2-4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat
51. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats
52. Cerebrovascular hemodynamics and ischemic tolerance: Lipopolysaccharide-induced resistance to focal cerebral ischemia is not due to changes in severity of the initial ischemic insult, but is associated with preservation of microvascular perfusion
53. Effects of lipopolysaccharide priming on acute ischemic brain injury
54. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats
55. Superoxide anion production during reperfusion is reduced by an antineutrophil antibody after prolonged cerebral ischemia
56. Electrochemical monitoring of superoxide anion production and cerebral blood flow: Effect of interleukin-1β pretreatment in a model of focal ischemia and reperfusion
57. Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat
58. The enlimomab acute stroke trial: Final results
59. Oxygen radicals in cerebral ischemia
60. Protective effect of a new anti-oxidant on the rat brain exposed to ischemia-reperfusion injury: Inhibition of free radical formation and lipid peroxidation
61. Relationship between free radical production and lipid peroxidation during ischemia-reperfusion injury in the rat brain
62. Oxygen radical mechanisms of brain injury following ischemia and reperfusion
63. Concentration changes of malondialdehyde across the cerebral vascular bed and shedding of L-selectin during carotid endarterectomy
64. Free radical damage to protein and DNA: Mechanisms involved and relevant observations on brain undergoing oxidative stress
65. APE/Ref-1 responses to ischemia in rat brain
66. Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats
67. Protective effects of 5-iodo-6-amino-1,2-benzopyrone, an inhibitor of poly(ADP-ribose) synthetase against peroxynitrite-induced glial damage and stroke development
68. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain
69. Structural alterations in synaptosomal membrane-associated proteins and lipids by transient middle cerebral artery occlusion in the cat
70. Generation of nitric oxide and superoxide during reperfusion after focal cerebral ischemia in rats
71. The double-edged role of nitric oxide in brain function and superoxide-mediated injury
72. Endothelial dysfunction in cerebral vessels following carotid artery infusion of phorbol ester in rabbits: The role of polymorphonuclear leukocytes
73. Control of coronary vascular tone by nitric oxide
74. Superoxide dismutase and hydrogen peroxide cause rapid nitric oxide breakdown, peroxynitrite production and subsequent cell death
75. The NF-κB activation pathway: Its regulation and role in inflammation and cell survival
76. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolyfic degradation of IκB-α
77. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-κB activation
78. Structure, regulation and function of NF-κB
79. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB
80. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation
81. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation
82. Nuclear factor-κB activation during cerebral reperfusion: Effect of attenuation with N-acetylcysteine treatment
83. Pathophysiology of ischaemia-reperfusion injury
84. Inflammatory reaction after brain damage and prospective therapy against damage impending cerebral infarction
85. NF-κB is activated and promotes cell death in focal cerebral ischemia
86. Nuclear factor-κB/Rel proteins: A point of convergence of signaling pathways relevant in neuronal function and dysfunction
87. Is nuclear factor-κB a good treatment target in brain ischemia/reperfusion injury?
88. Tumor necrosis factor α and interleukin-Iβ regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EBP-β and NF-κB
89. Inducible loss of NF-κB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes
90. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors
91. Protective effect of a new anti-oxidant on the rat brain exposed to ischemia-reperfusion injury: Inhibition of free radical formation and lipid peroxidation
92. α-lipoic acid protects against reperfusion injury following cerebral ischemia in rats
93. Prevention of ischemia/reperfusion-induced alterations in synaptosomal membrane-associated proteins and lipids by N-tert-butyl-alpha-phenylnitrone and difluoromethylornithine
94. Effects of dimethylthiourea on selective neuronal vulnerability in forebrain ischemia in rats
95. In vivo detection of superoxide anion production by the brain using a cytochrome c electrode
96. Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol
97. Brain lactic acidosis and ischemic cell damage, 1: Biochemistry and neurophysiology
98. Clinical restitution following cerebral ischemia in hypo-, normo- and hyperglycemic rats
99. Hyperglycemia and focal brain ischemia
100. Poor hemodynamic and metabolic recovery after global incomplete cerebral ischemia associated with short-term diabetes in dogs
101. Perfusion deficit parallels exacerbation of cerebral ischemia/reperfusion injury in hyperglycemic rats
102. Hyperglycemia and the vascular effects of cerebral ischemia
103. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes
104. Cerebrovascular disorders in patients with diabetes mellitus
105. Nonenzymatically gylcated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelium cells
106. G-nitro-L-arginine methyl ester decreases ischemic damage in reversible focal cerebral ischemia in hyperglycemic rats
107. Rapid monitoring of diffusion, DC potential, and blood oxygenation changes during global ischemia: Effects of hypoglycemia, hyperglycemia, and TTX
108. Ischemia in normoglycemic and hyperglycemic rats: Plasma energy substrates and hormones
109. Molecular mechanisms of acidosis-mediated damage
110. Changes in labile energy metabolites, redox state and intracellular pH in postischemic brain of normo- and hyperglycemic rats
111. Preischemic hyperglycemia leads to delayed postischemic hyperthermia
112. Influence of moderate hypothermia on ischemic brain damage incurred under hyperglycemic conditions
113. Hydroxyl radical formation in hyperglycemic rats during middle cerebral artery occlusion/reperfusion
114. Advanced glycation end-products: A review
115. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: A model for intracellular glycosylation in diabetes
116. Cellular receptors for advanced glycation end products: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
117. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues
118. Distribution of advanced glycation end products in the cerebellar neurons of dogs
119. Receptors for advanced glycosylation end products in human brain: Role in brain homeostasis
120. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease
121. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
122. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways
123. The role of oxidative stress and NF-κB activation in late diabetic complications
124. Advanced glycation end products and their recognition by macrophage and macrophage-derived cells
125. Receptors for advance glycation end-products (AGE): Expression by endothelial cells in non-diabetic uraemic patients
126. Roles of the AGE-RAGE system in vascular injury in diabetes
127. Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo
128. Neurotoxicity of advanced glycation end products during focal stroke and neuroprotective effects of aminoguanidine
129. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes
130. The role of oxidative stress and NF-κB activation in late diabetic complications
131. N(ε)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression
132. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
133. Hyperglycemia triggers massive neutrophil deposition in brain following transient ischemia in rats
134. Hyperglycemia increased the responsiveness of isolated rabbit's pulmonary arterial rings to serotonin
135. Hyperglycemia promotes elevated generation of TXA2 in isolated rat uteri
136. Diabetes and vascular disease: Functional alterations in adrenergic neurotransmission and endothelium
137. Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells
138. Spreading depression-induced gene expression is regulated by plasma glucose
139. Effect of selective inhibition of cyclooxygenase 2 on temporary focal cerebral ischemia in rats
140. Cyclooxygenase-2 is induced globally in infarcted human brain
141. Effect of plasma glucose on infarct size in focal cerebral ischemia-reperfusion
142. Insulin protects brain tissue against focal ischemia in rats
143. Insulin, blood glucose levels, and ischemic brain damage
144. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: The Glucose Insulin in Stroke Trial (GIST)
145. Role of proinflammatory cytokines in cerebral ischemia: A review
146. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: Kinetics of secretion and relation to the extent of brain damage and outcome of disease
147. Impairments of the protein C system and fibrinolysis in infection-associated stroke
148. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
149. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
150. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
151. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
152. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: The West Birmingham Stroke Project
153. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
154. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
155. Recent infection as a risk factor for cerebrovascular ischemia
156. Acute infection as a risk factor for ischemic stroke
157. Precipitants of brain infarction: Roles of preceding infection/inflammation and recent psychological stress
158. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: Clinical and biochemical studies
159. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: Effects of ischemia and peripheral lipopolysaccharide administration
160. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?
161. Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications
162. Activation of the NF-κB pathway by inflammatory stimuli in human neutrophils
163. Microvascular responses to cerebral ischemia/inflammation
164. Thrombin-induced p65 homodimer binding to downstream NF-κB site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion
165. Acute-phase proteins before cereral ischemia in stroke-prone rats: Identification by proteomics
166. Endotoxin activation of endothelium for polymorphonuclear leukocyte transendothelial migration and modulation by interferon-gamma
167. Interleukin-6 related brain damage in ischemic stroke is independent of acute infections
168. Inflammatory mechanisms in acute cerebral hemorrhage are associated with poor outcome and high volume of residual necrosis
169. Inflammation, endothelial dysfunction and efficacy of thrombolytic therapy